GlassScriptPhysician profile
George M Rodgers
NPI 1578512190
$133,182.35
in general payments reported to CMS, 2019-2025
23 companies · $5,926 in 2025
The $5,926 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $8,248 · 2021: $17K · 2022: $34K · 2023: $27K · 2024: $10K · 2025: $5,926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $29K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,756 · Honoraria: $3,336 · Travel and Lodging: $2,143 · Food and Beverage: $1,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $28,936.80 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,755.64 |
| Honoraria | $3,336.00 |
| Travel and Lodging | $2,142.72 |
| Food and Beverage | $1,689.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $29,408.82 | 2021-2024 | Monoferric |
| Genzyme Corporation | $20,826.50 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $19,555.82 | 2019-2025 | Ultomiris |
| Grifols, S.A. | $16,530.44 | 2021-2025 | Thrombate III |
| Dova Pharmaceuticals | $15,736.15 | 2019-2021 | |
| Genentech USA, INC. | $7,371.40 | 2019-2020 | |
| Astrazeneca Ab | $6,548.75 | 2019 | |
| Sobi, INC | $3,700.00 | 2022 | |
| Bioverativ Therapeutics INC. | $3,540.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $3,530.22 | 2019-2024 | |
| Fresenius USA INC. | $3,000.00 | 2019 | |
| Astrazeneca Uk Limited | $2,537.65 | 2019 | |
| Octapharma USA, INC. | $316.48 | 2019-2021 | |
| Grifols Shared Services North America, INC. | $186.78 | 2019-2020 | |
| Bio Products Laboratory USA, INC. | $130.54 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $89.74 | 2019-2021 | |
| Recordati_rare_diseases_inc. | $87.27 | 2025 | Enjaymo |
| Sanofi-Aventis U.S. LLC | $85.79 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Rodgers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.